Related Experiment Videos

Mylicon drops in the treatment of infant colic

N Becker1, P Lombardi, E Sidoti

  • 1Albert Einstein College of Medicine, New York, New York.

Clinical Therapeutics
|January 1, 1988
PubMed

Insights

Simethicone, marketed as Mylicon Drops, effectively treats infant colic. Most infants experienced symptom improvement or resolution within seven days, enhancing infant and family quality of life.

Area of Science:

  • Pediatrics
  • Pharmacology

Background:

  • Infant colic is a common condition affecting newborns.
  • Effective treatments for infant colic are sought after by caregivers.
  • Simethicone is a widely used over-the-counter medication for gas relief.

Purpose of the Study:

  • To evaluate the efficacy of simethicone (Mylicon Drops) in treating infant colic.
  • To assess the impact of simethicone on infant colic symptoms and overall quality of life.

Main Methods:

  • An open-label trial involving 51 healthy infants aged 2-12 weeks.
  • A one-week study period with caregiver-reported outcomes.
  • Dosage administered: 0.3 ml of simethicone with each feeding.

Main Results:

  • Symptom improvement or resolution observed in 78% of infants after one day.
  • Symptom improvement or resolution observed in 86% of infants after seven days.
  • Caregivers reported noticeable improvements in infant and family quality of life.

Conclusions:

  • Simethicone (Mylicon Drops) is highly effective in managing infant colic symptoms.
  • Treatment with simethicone significantly improves the quality of life for both infants and their families.
  • The recommended dosage of 0.3 ml with each feeding is associated with positive outcomes.

Related Concept Videos